Zacks: Analysts Anticipate Aurinia Pharmaceuticals Inc (AUPH) to Post -$0.16 EPS

Brokerages expect Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP) to report ($0.16) earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Three analysts have provided estimates for Aurinia Pharmaceuticals’ earnings. The lowest EPS estimate is ($0.20) and the highest is ($0.11). Aurinia Pharmaceuticals reported earnings of ($0.04) per share in the same quarter last year, which would indicate a negative year-over-year growth rate of 300%. The firm is scheduled to report its next quarterly earnings report on Thursday, March 21st.

According to Zacks, analysts expect that Aurinia Pharmaceuticals will report full-year earnings of ($0.74) per share for the current financial year, with EPS estimates ranging from ($0.78) to ($0.62). For the next fiscal year, analysts anticipate that the firm will post earnings of ($0.73) per share, with EPS estimates ranging from ($0.90) to ($0.45). Zacks Investment Research’s EPS averages are an average based on a survey of research analysts that cover Aurinia Pharmaceuticals.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last released its earnings results on Thursday, November 8th. The biotechnology company reported ($0.21) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.17) by ($0.04). The business had revenue of $0.38 million during the quarter, compared to analysts’ expectations of $0.07 million. Aurinia Pharmaceuticals had a negative net margin of 7,280.85% and a negative return on equity of 36.10%.

A number of analysts have recently issued reports on the company. Zacks Investment Research upgraded Aurinia Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, November 20th. BidaskClub lowered Aurinia Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Friday, January 25th. Finally, ValuEngine upgraded Aurinia Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Friday, November 16th. Two research analysts have rated the stock with a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $12.94.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. FMR LLC lifted its holdings in shares of Aurinia Pharmaceuticals by 2.1% in the third quarter. FMR LLC now owns 4,680,959 shares of the biotechnology company’s stock valued at $31,082,000 after purchasing an additional 95,650 shares in the last quarter. Franklin Resources Inc. lifted its holdings in shares of Aurinia Pharmaceuticals by 6.1% in the third quarter. Franklin Resources Inc. now owns 1,838,500 shares of the biotechnology company’s stock valued at $12,208,000 after purchasing an additional 105,300 shares in the last quarter. Creative Planning increased its stake in shares of Aurinia Pharmaceuticals by 10.2% in the fourth quarter. Creative Planning now owns 167,657 shares of the biotechnology company’s stock worth $1,143,000 after acquiring an additional 15,457 shares during the last quarter. Jane Street Group LLC acquired a new position in shares of Aurinia Pharmaceuticals in the third quarter worth $182,000. Finally, Virtu Financial LLC acquired a new position in shares of Aurinia Pharmaceuticals in the fourth quarter worth $105,000. Institutional investors own 25.08% of the company’s stock.

Shares of AUPH traded up $0.06 during mid-day trading on Monday, reaching $6.60. The company’s stock had a trading volume of 410,700 shares, compared to its average volume of 1,294,439. The firm has a market capitalization of $553.19 million, a P/E ratio of -7.17 and a beta of 1.38. Aurinia Pharmaceuticals has a 1 year low of $5.01 and a 1 year high of $7.85.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc, a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutic drugs for the treatment of autoimmune diseases in Canada, the United States, China, and Switzerland. The company is developing voclosporin, a calcineurin inhibitor for the treatment of lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis.

Featured Story: Cost of Capital

Get a free copy of the Zacks research report on Aurinia Pharmaceuticals (AUPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit